Breztri Aerosphere Asthma FDA Approval Impacts India Care

Global pharma giant AstraZeneca has achieved a major milestone with the Breztri Aerosphere asthma FDA approval, expanding treatment options for asthma patients worldwide.

The U.S. Food and Drug Administration (FDA) has approved the triple-combination inhaler for maintenance therapy in adults and children aged 12 and older, strengthening its presence beyond COPD care.

The Breztri Aerosphere brings together budesonide, glycopyrrolate, and formoterol fumarate in a single inhaler.

This combination unites an inhaled corticosteroid, a long-acting beta2-agonist, and a long-acting muscarinic antagonist to improve long-term asthma control. By simplifying treatment into one device, it aims to improve adherence and outcomes.

First cleared in 2020 for chronic obstructive pulmonary disease, Breztri has already been used by over 6.8 million patients globally in 2025. With the Breztri Aerosphere asthma FDA approval, the therapy is expected to influence asthma management approaches, including in India where respiratory diseases remain a growing concern.

Also Read: Consumer Trust in OTC Products: The Science Behind Safety

The approval is supported by Phase III KALOS and LOGOS trials. These studies showed statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies. Patients also saw rapid benefits, with noticeable improvement within five minutes after the first dose.

The inhaler is designed strictly for maintenance treatment and does not replace a rescue inhaler for sudden symptoms.

Njira Lugogo, Clinical Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, said: “Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms.

"The FDA approval of Breztri as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner.”

From AstraZeneca, Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “As the fastest growing fixed-dose triple-combination therapy in COPD, Breztri is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients.

"The FDA’s approval of Breztri in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases.”